Stock comparison
IDEXX Laboratories
Teleflex
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
TFX
Teleflex
Market cap
$5.74B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TFX | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 24F | IDXX |
| Benjamin Graham | 72B | 26F | IDXX |
| Philip Fisher | 67B | 23F | IDXX |
| Peter Lynch | 63C | 1F | IDXX |
| Joel Greenblatt | 75B | 27F | IDXX |
| Charlie Munger | 79B | 18F | IDXX |
| Terry Smith | 76B | 15F | IDXX |
Side-by-side metrics
| Metric | IDXX | TFX |
|---|---|---|
| Market cap | $42.11B | $5.74B |
| P/E (TTM) | 39.0x | - |
| EV/EBIT | 31.6x | 21.9x |
| ROIC (TTM) | 40.66% | 2.73% |
| Gross margin | 62.05% | 53.27% |
| Net margin | 24.63% | -35.89% |
| Revenue CAGR 5y | 7.56% | -8.23% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 1.05% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Revenue CAGR 5y7.56%vs -8.23%+192%
- Net margin24.63%vs -35.89%+169%
- ROIC (TTM)40.66%vs 2.73%+93%
- Market cap$42.11Bvs $5.74B+86%
TFX leads on
- P/E (TTM)-vs 39.0x+115%
- Dividend yield1.05%vs 0.0%+100%
- Debt / Equity0.1xvs 0.7x+92%
- EV/EBIT21.9xvs 31.6x+31%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.